

5-Minute Journal Club: Defining the Current and Future Role of
TROP2-Directed Antibody-Drug Conjugates in Breast Cancer — Issue 4

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following adverse events of special interest is observed with datopotamab deruxtecan (Dato-DXd)?
 - a. Oral mucositis/stomatitis
 - b. Interstitial lung disease (ILD)
 - c. Ocular surface events
 - d. All of the above**
 - e. None of the above
2. Which of the following neoadjuvant regimens demonstrated the greatest clinical benefit for patients with triple-negative breast cancer (TNBC) in the I-SPY 2.2 Phase II trial?
 - a. Dato-DXd monotherapy
 - b. Dato-DXd with durvalumab**
 - c. Neither regimen demonstrated meaningful clinical benefit as neoadjuvant therapy
3. Which of the following descriptions best reflects the study design of the OptimICE-RD trial?
 - a. Phase II dose-optimization study evaluating 2 different schedules of sacituzumab govitecan for advanced TNBC
 - b. Phase III study of sacituzumab govitecan versus investigator's choice of chemotherapy for advanced, PD-L1-negative TNBC
 - c. Phase III study of sacituzumab govitecan with pembrolizumab versus pembrolizumab with or without capecitabine for residual TNBC**
4. Which of the following recommendations is appropriate for the management of ocular surface events associated with Dato-DXd?
 - a. Avoid wearing contact lenses
 - b. Use prophylactic saline eyedrops
 - c. Use prophylactic steroid eyedrops
 - d. a and b only**
 - e. a and c only
5. Which of the following adverse events is more common with trastuzumab deruxtecan than with Dato-DXd?
 - a. Oral mucositis/stomatitis
 - b. ILD**
 - c. Ocular surface events